CN1551789A - 治疗不孕症的单剂量芳香酶抑制剂 - Google Patents

治疗不孕症的单剂量芳香酶抑制剂 Download PDF

Info

Publication number
CN1551789A
CN1551789A CNA028120825A CN02812082A CN1551789A CN 1551789 A CN1551789 A CN 1551789A CN A028120825 A CNA028120825 A CN A028120825A CN 02812082 A CN02812082 A CN 02812082A CN 1551789 A CN1551789 A CN 1551789A
Authority
CN
China
Prior art keywords
aromatase inhibitor
use according
single dose
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028120825A
Other languages
English (en)
Chinese (zh)
Inventor
Rf
R·F·卡斯普
M
M·F·M·米特瓦利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of CN1551789A publication Critical patent/CN1551789A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA028120825A 2001-04-17 2002-04-17 治疗不孕症的单剂量芳香酶抑制剂 Pending CN1551789A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28428201P 2001-04-17 2001-04-17
US60/284,282 2001-04-17

Publications (1)

Publication Number Publication Date
CN1551789A true CN1551789A (zh) 2004-12-01

Family

ID=23089583

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028120825A Pending CN1551789A (zh) 2001-04-17 2002-04-17 治疗不孕症的单剂量芳香酶抑制剂

Country Status (32)

Country Link
US (1) US8008333B2 (enExample)
EP (1) EP1383578B1 (enExample)
JP (1) JP2004529924A (enExample)
KR (1) KR20040025916A (enExample)
CN (1) CN1551789A (enExample)
AR (1) AR034036A1 (enExample)
AT (1) ATE409066T1 (enExample)
AU (1) AU2002249043B2 (enExample)
BG (1) BG108323A (enExample)
BR (1) BR0208920A (enExample)
CA (1) CA2444980C (enExample)
CY (1) CY1108648T1 (enExample)
CZ (1) CZ20033107A3 (enExample)
DE (1) DE60229047D1 (enExample)
DK (1) DK1383578T3 (enExample)
EA (1) EA011310B1 (enExample)
EE (1) EE200300505A (enExample)
ES (1) ES2311599T3 (enExample)
HR (1) HRP20030839A2 (enExample)
HU (1) HUP0304003A2 (enExample)
IL (1) IL158396A0 (enExample)
MX (1) MXPA03009447A (enExample)
NO (1) NO20034246L (enExample)
NZ (1) NZ552873A (enExample)
PL (1) PL366744A1 (enExample)
PT (1) PT1383578E (enExample)
SI (1) SI1383578T1 (enExample)
SK (1) SK14242003A3 (enExample)
UA (1) UA82648C2 (enExample)
WO (1) WO2002083241A1 (enExample)
YU (1) YU81203A (enExample)
ZA (1) ZA200307516B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003247404A1 (en) * 2002-07-02 2004-01-23 Pharmacia & Upjohn Company Llc Infertility treatment with exemestane
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2007000056A1 (en) * 2005-06-28 2007-01-04 Casper Robert F Aromatase inhibitors for emergency contraception
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
AU2011256088B2 (en) * 2010-05-20 2015-03-26 University Of Saskatchewan Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
US10004723B2 (en) 2013-04-19 2018-06-26 University Of Saskatchewan Aromatase inhibitor-releasing intravaginal device
US20160022644A1 (en) * 2014-07-22 2016-01-28 Tsu-I Catherine Wang Oral Transmucosal Compositions Including Aromatase Inhibitors for Treating Female Infertility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US4602025A (en) * 1984-06-18 1986-07-22 Eli Lilly And Company Aromatase inhibitors
US4845227A (en) * 1984-06-18 1989-07-04 Eli Lilly And Company Aromatase inhibitors from azoles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
GB8726505D0 (en) * 1987-11-12 1987-12-16 Ici Plc Naphtho(2 1-b)furan derivatives
DE4330237C2 (de) 1993-09-02 1995-11-30 Schering Ag 1-Methylsubstituierte Androsta-1,4-dien-3,17-dione, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
AU2407997A (en) * 1996-04-30 1997-11-19 Takeda Chemical Industries Ltd. Combined use of gnrh agonist and antagonist
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation

Also Published As

Publication number Publication date
WO2002083241A1 (en) 2002-10-24
MXPA03009447A (es) 2004-05-24
NO20034246L (no) 2003-12-15
DE60229047D1 (de) 2008-11-06
HUP0304003A2 (hu) 2004-04-28
US20040171660A1 (en) 2004-09-02
SI1383578T1 (sl) 2008-12-31
ES2311599T3 (es) 2009-02-16
IL158396A0 (en) 2004-05-12
DK1383578T3 (da) 2008-11-03
SK14242003A3 (sk) 2004-03-02
BG108323A (bg) 2004-12-30
NO20034246D0 (no) 2003-09-23
CA2444980C (en) 2010-08-17
US8008333B2 (en) 2011-08-30
PL366744A1 (en) 2005-02-07
ATE409066T1 (de) 2008-10-15
EA011310B1 (ru) 2009-02-27
JP2004529924A (ja) 2004-09-30
BR0208920A (pt) 2004-04-20
YU81203A (sh) 2006-05-25
KR20040025916A (ko) 2004-03-26
NZ552873A (en) 2008-05-30
EE200300505A (et) 2004-02-16
HRP20030839A2 (en) 2005-08-31
EP1383578A1 (en) 2004-01-28
EP1383578B1 (en) 2008-09-24
PT1383578E (pt) 2008-10-08
CZ20033107A3 (en) 2004-03-17
UA82648C2 (uk) 2008-05-12
EA200301128A1 (ru) 2004-04-29
AU2002249043B2 (en) 2008-01-10
ZA200307516B (en) 2004-09-27
CA2444980A1 (en) 2002-10-24
AR034036A1 (es) 2004-01-21
CY1108648T1 (el) 2014-04-09

Similar Documents

Publication Publication Date Title
CN1671371A (zh) 芳香酶抑制剂和双膦酸酯的组合
CN1549734A (zh) 增强辅助生殖的芳香酶抑制剂
US8008333B2 (en) Single dose aromatase inhibitor for treating infertility
US7820706B2 (en) Multiple dose aromatase inhibitor for treating infertility
US8871750B2 (en) Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
AU2002249041A1 (en) Aromatase inhibition to enhance assisted reproduction
AU2002249043A1 (en) Single dose aromatase inhibitor for treating infertility
HK1067568A (en) Single dose aromatase inhibitor for treating infertility
EP1759734A2 (en) Aromatase inhibition to enhance assisted reproduction
HK1067987B (en) Aromatase inhibition to enhance assisted reproduction
HK1050329A (en) Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1067568

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1067568

Country of ref document: HK